Press Releases

Unedited news and product information from vendors.

Reportlinker Adds Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
Dec 08, 2010 (01:12 PM EST)


NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

http://www.reportlinker.com/p0336652/Pharmaceutical-Industry---2010-Yearbook---Therapeutic-Market-Landscape-Key-Pipeline-Drugs-Top-Pharma-Companies-and-Key-Mergers-and-Acquisitions.html

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions" that provides key data, information and analysis of the major trends and issues affecting the Pharmaceutical market. The report provides a comprehensive insight into the history of Pharmaceutical Industry Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of Pharmaceutical Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions in terms of its market size, and the major market drivers and barriers.. The report also looks into Pharmaceutical drug pipeline along with analysis on the pipeline by indication, phase of development and geography of development.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of the report includes:

- Detailed overview of pharmaceutical industry 2009-2010.

- Annualized market data

- Key market drivers and restraints, challenges and trends shaping the Pharmaceutical market

- Pipeline analysis of the along with segmentation by indication, phase and geography

- Competitive landscape analysis with competitive profiling of leading companies such as

- Analysis of M&A deals from 2009-2010 along with segmentation by value geography and companies

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Develop better strategies pharmaceutical industry

- Develop market-entry and market expansion strategies

- Understand the factors shaping the Pharmaceutical industry market

- Reinforce R&D pipeline

- Identify the key players best positioned to take the advantage of the opportunities in the pharmaceutical market

- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

1 Table of Contents 4

1.1 List of Tables 9

1.2 List of Figures 10

2 Introduction 12

2.1 GBI Research Report Guidance 12

3 Global Pharmaceutical Market Overview 2009 13

3.1 Introduction 13

3.2 Total Sales Of Pharmaceutical Drugs In 2009 13

3.3 Market Share By Therapeutic Areas, 2009 14

3.4 Top Selling Drugs Of 2009 15

3.4.1 Lipitor (atorvastin) 15

3.4.2 Plavix (clopidrogel) 15

3.4.3 Nexium (esmoprazole) 15

3.4.4 Advair (fluticasone salmetrol) 15

3.4.5 Seroquel (quetiapine) 15

3.4.6 Diovan (valsartan) 15

3.4.7 Enbrel (etanercept) 15

3.4.8 Remicade (infliximab) 15

3.4.9 Crestor (rosuvastatin) 15

3.4.10 Zyprexa (olanzapine) 15

3.5 Key Patent Expirations Of Drugs In 2009 16

4 Key Therapeutic Landscape 17

4.1 Cardiovascular Disease Therapeutics 17

4.1.1 Drivers for Cardiovascular Therapeutics Market 18

4.1.2 Restraints For Cardiovascular Therapeutics Market 20

4.1.3 Merger And Acquisition Deals Landscape For Cardiovascular Therapeutics, 2009-2010 21

4.2 Respiratory Disease Therapeutics 23

4.2.1 Drivers For Respiratory Therapeutics Market 24

4.2.2 Restraints For Respiratory Therapeutics Market 25

4.2.3 Merger And Acquisition Deals Landscape For Respiratory Therapeutics, 2009-2010 26

4.3 Musculoskeletal Disorder Therapeutics 27

4.3.1 Drivers For Musculoskeletal Therapeutics Market 29

4.3.2 Restraints For Musculoskeletal Therapeutics Market 30

4.3.3 Merger And Acquisition Deals Landscape For Musculoskeletal Therapeutics, 2009-2010 30

4.4 Oncology Therapeutics 32

4.4.1 Drivers For Oncology Therapeutics Market 34

4.4.2 Restraints For Oncology Therapeutics Market 35

4.4.3 Merger And Acquisition Deals Landscape For Oncology, 2009-2010 36

4.5 Central Nervous System Therapeutics 38

4.5.1 Drivers For CNS Therapeutics Market 40

4.5.2 Restraints For CNS Therapeutics Market 41

4.5.3 Merger And Acquisition Deals Landscape For Central Nervous System (CNS) Therapeutics, 2009-2010 42

4.6 Autoimmune Disease Therapeutics 43

4.6.1 Drivers For Autoimmune Therapeutics Market 45

4.6.2 Restraints for Autoimmune Therapeutics Market 46

4.6.3 Merger and Acquisition Deals Landscape for Autoimmune Diseases Therapeutics, 2009-2010 47

4.7 Gastrointestinal Disorder Therapeutics 48

4.7.1 Drivers For Gastrointestinal Therapeutics Market 50

4.7.2 Restraints For Gastrointestinal Therapeutics Market 51

4.7.3 Merger And Acquisition Deals Landscape For Gastrointestinal Therapeutics, 2009-2010 51

4.8 Dermatology Therapeutics 53

4.8.1 Drivers For Dermatology Therapeutics Market 55

4.8.2 Restraints For Dermatology Therapeutics Market 56

4.8.3 Merger And Acquisition Deals Landscape For Dermatology Therapeutics, 2009-2010 56

4.9 Opthalmology Therapeutics 57

4.9.1 Drivers For Ophthalmology Therapeutics Market 60

4.9.2 Restraints For Ophthalmology Therapeutics Market 60

4.9.3 Merger And Acquisition Deals Landscape For Ophthalmology Therapeutics, 2009-2010 61

4.10 Men's Health Therapeutics 62

4.10.1 Drivers for Men's Health Market 64

4.10.2 Restraints for Men's Health Market 65

4.10.3 Merger And Acquisition Deals Landscape For Men's Health Therapeutics, 2009-2010 65

4.11 Women's Health Therapeutics 66

4.11.1 Drivers For Women's Health Market 68

4.11.2 Restraints For Women's Health Market 69

4.11.3 Merger And Acquisition Deals Landscape For Women's Health Therapeutics, 2009-2010 69

4.12 Blood Disorders Therapeutics 70

4.12.1 Drivers For Blood Disorders Therapeutics 72

4.12.2 Restraints For Blood Disorders Therapeutics 73

4.12.3 Merger And Acquisition Deals Landscape For Blood Disorders Therapeutics Market, 2009-2010 74

4.13 Urological Therapeutics Market 76

4.13.1 Drivers For Urology Therapeutics 78

4.13.2 Restraints for Urology Therapeutics Market 79

4.13.3 Merger And Acquisition Deals Landscape For Urology Therapeutics, 2009-2010 80

5 Key Promising Drugs In The Pipeline 82

5.1 Cardiovascular Therapeutics 82

5.1.1 Tekturna/Rasilez (acute heart failure) 82

5.1.2 Lixivaptan (acute heart failure) 83

5.1.3 Relaxin (acute heart failure) 83

5.1.4 Cinaciguat (acute heart failure) 84

5.1.5 Xarelto (atrial fibrillation) 85

5.1.6 Pradaxa (atrial fibrillation) 86

5.1.7 Stedicor (atrial fibrillation) 86

5.1.8 Kynapid (atrial fibrillation) 87

5.1.9 Edoxaban (atrial fibrillation) 88

5.2 Respiratory Therapeutics 89

5.2.1 Flutiform (fluticasone propionate/formoterol fumarate inhalation aerosol) (asthma) 89

5.2.2 MFF 258 (Mometasone furoate/formoterol fumarate) (asthma) 90

5.2.3 Aclidinium bromide (Chronic Obstructive Pulmonary Disease-COPD) 91

5.2.4 GW642444 ('444) (COPD) 92

5.2.5 Iloprost (Pulmonary Arterial Hypertension) 93

5.2.6 ACT-064992 (Pulmonary Arterial Hypertension) 93

5.2.7 Denufosol Tetrasodium Inhalation Solution (INS37217) (Cystic Fibrosis) 94

5.2.8 VX-770 (Cystic Fibrosis) 95

5.3 Musculoskeletal Disorder Therapeutics 96

5.3.1 Catena/Sovrima (Idebenone) 96

5.3.2 IPlex(TM) (mecasermin rinfabate) 96

5.3.3 CG5503 97

5.3.4 Vicodin CR 97

5.3.5 T-614 (iguratimod) 98

5.4 Oncology Therapeutics 99

5.4.1 Provenge (sipuleucel-T) 99

5.4.2 Gemzar (gemcitabine hydrochloride) 100

5.4.3 Aflibercept 101

5.4.4 Recentin (Cediranib) 101

5.5 Central Nervous System (CNS) Therapeutics 102

5.5.1 Staccato Loxapine, AZ-004 (Loxapine) 102

5.5.2 Lurasidone 103

5.5.3 Clonicel 103

5.5.4 ABT-089 (Pozanicline) 104

5.5.5 Safinamide 105

5.5.6 Pimavanserin 106

5.5.7 Stedesa (Eslicarbazepine Acetate) 106

5.5.8 Comfyde (Carisbamate) 107

5.6 Autoimmune Disease Therapeutics 109

5.6.1 Benlysta (belimumab) 109

5.6.2 Voclosporin (LX211, LUVENIQ, ISA-247) 110

5.6.3 T-614 (iguratimod) 111

5.6.4 Prograf (Tacrolimus) 112

5.6.5 Mylinax (Cladribine Oral Formulation) 113

5.7 Gastrointestinal Disorder Therapeutics 114

5.7.1 Myoconda (For Crohn's Disease) 114

5.7.2 Traficet-EN (CCX282) (For Crohn's Disease) 115

5.7.3 Linaclotide (Linaclotide Acetate) (For Irritable Bowel Syndrome) 116

5.7.4 Asimadoline (For Irritable Bowel Syndrome) 117

5.7.5 XP19986 (For GERD) 118

5.7.6 AZD3355 (For GERD) 119

5.7.7 Prograf (Tacrolimus) (For Ulcerative Colitis) 120

5.7.8 Vedolizumab (For Ulcerative Colitis) 121

5.8 Dermatology Therapeutics 121

5.8.1 Voclosporin (LX211, LUVENIQ, ISA-247) 121

5.8.2 ABT-874 (J-695, Briakinumab) 121

5.8.3 CF-101 122

5.8.4 Orencia (abatacept, CTLA4-Ig, BMS-188667) 122

5.8.5 Cimzia (CDP870 certolizumab pegol) 122

5.8.6 Apremilast (CC10004, ACR20) 122

5.8.7 INCB18424 122

5.8.8 PH-10 122

5.8.9 Hivenyl 122

5.8.10 TF002 123

5.9 Opthalmology Therapeutics 123

5.9.1 Saflutan (tafluprost) (For Glaucoma) 123

5.9.2 Retaane (Macular Degeneration) 124

5.9.3 Photrex (SnET2) (Macular Degeneration) 124

5.9.4 Vekacia (cyclosporine A) (Allergic Conjunctivitis) 125

5.9.5 FOV1101 (Prednisporin) (Allergic Conjunctivitis) 126

5.10 Men's Health Therapeutics 127

5.10.1 Avanafil (For Erectile Dysfunction) 127

5.10.2 Zoraxel (For Erectile Dysfunction) 128

5.11 Women's Health Therapeutics 129

5.11.1 Visanne (For Endometriosis) 129

5.11.2 Proellex (For Endometriosis) 129

5.11.3 Viviant (bazedoxifene) (For Osteoporosis) 130

5.12 Blood Disorders Therapeutics 131

5.12.1 Hematide (peginesatide) (For Anemia) 131

5.12.2 NecLip-rFVIIa (LongSeven) (For Hemophilia) 132

5.13 Urological Disorders Therapeutics 132

5.13.1 NX-1207 (For BPH) 132

5.13.2 YM178 (For Urinary Incontinence) 133

5.13.3 CXA-101(For UTI) 134

6 Merger and Acquisition Deals Landscape, 2009-2010 135

6.1 Key Mergers And Acquisitions Deals Of 2009 137

6.1.1 Pfizer Completes Acquisition Of Wyeth 137

6.1.2 Roche Acquires Genentech 138

6.1.3 Merck Completed Merger With Schering Plough Corporation 138

6.1.4 Abbott Acquires Solvay Pharmaceuticals 139

6.1.5 GSK Acquired Stiefel Laboratories 139

7 Major Pharmaceutical Companies 140

7.1 Pfizer 140

7.1.1 Annual Revenue 140

7.1.2 Top Selling Drugs of Pfizer 140

7.1.3 Key Pipeline Drugs Of Pfizer 141

7.1.4 Merger And Acquisition Deals Landscape Of Pfizer 142

7.2 Johnson and Johnson (J&J) 143

7.2.1 Annual Revenue 143

7.2.2 Top Selling Drugs of J&J 143

7.2.3 Key Pipeline Drugs Of J&J 144

7.2.4 Merger And Acquisition Deals Landscape Of J&J 145

7.3 Roche 146

7.3.1 Annual Revenue 146

7.3.2 Top Selling Drugs Of Roche 146

7.3.3 Key Pipeline Drugs Of Roche 147

7.3.4 Merger And Acquisition Deals Landscape Of Roche 148

7.4 GlaxoSmithKline (GSK) 148

7.4.1 Annual Revenue 148

7.4.2 Top Selling Drugs Of GSK 148

7.4.3 Key Pipeline Drugs Of GSK 150

7.4.4 Merger And Acquisition Landscape Of GSK 150

7.5 Novartis 151

7.5.1 Annual Revenue 151

7.5.2 Top Selling Drugs Of Novartis 151

7.5.3 Key Pipeline Drugs Of Novartis 152

7.5.4 Merger And Acquisition Deals Landscape Of Novartis 153

7.6 Sanofi-Aventis 153

7.6.1 Annual revenues 153

7.6.2 Top Selling Drugs Of Sanofi-Aventis 153

7.6.3 Key Pipeline Drugs Of Sanofi-Aventis 155

7.6.4 Merger and Acquisition Deals Landscape of Sanofi-Aventis 155

7.7 AstraZeneca 156

7.7.1 Annual Revenue 156

7.7.2 Top Selling Drugs 156

7.7.3 Key Pipeline Drugs Of Astrazeneca 158

7.7.4 Merger And Acquisition Deals Landscape Of Astrazeneca 158

7.8 Abbott 158

7.8.1 Annual Revenues 158

7.8.2 Top Selling Drugs Of Abbott 158

7.8.3 Key Pipeline Drugs Of Abbott 159

7.8.4 Merger And Acquisition Deals Landscape Of Abbott 159

7.9 Merck 160

7.9.1 Annual Revenue 160

7.9.2 Top Selling Drugs Of Merck 160

7.9.3 Key Pipeline Drugs Of Merck 161

7.9.4 Merger and Acquisition Deals Landscape of Merck 161

7.10 Bayer HealthCare 162

7.10.1 Annual Revenue 162

7.10.2 Top Selling Drugs Of Bayer HealthCare 162

7.10.3 Key Pipeline Products Of Bayer Healthcare 163

7.10.4 Merger And Acquisition Deals Landscape Of Bayer 163

8 Key Regulations In Pharmaceutical Industry In 2009 164

8.1 Key Regulations in Us In 2009 164

8.1.1 Biologic License Applications (BLAs) Approved By FDA In 2009 164

8.1.2 New Molecular Entities (NMEs) Approved By FDA In 2009 165

8.1.3 Key Drug Recalls In US 166

8.1.4 Key Black Box Warnings issued by FDA in 2009 167

8.2 Key Regulations In Europe In 2009 169

8.2.1 Key Drug Approvals By European Medicines Agency (EMA) In 2009 169

8.2.2 Key Drug Recall In EU 170

8.3 Key Regulations In Japan In 2009 170

8.3.1 Key New Drug Application (NDA) And Drug Approvals By Ministry Of Health, Labour And Welfare (MHLW) Of Japan in 2009 170

9 Pharmaceutical Industry Yearbook 2010: Appendix 172

9.1 Market Definitions 172

9.2 Abbreviations 172

9.3 Research Methodology 173

9.3.1 Coverage 173

9.3.2 Secondary Research 173

9.3.3 Primary Research 173

9.3.4 Forecasts 174

9.4 Contact Us 177

9.5 Disclaimer 177

9.6 Sources 1771.1 List of Tables

Table 1: Pharmaceutical Market, Major Drug Patent Expirations, Global, 2009 16

Table 2: Top Selling Drugs of Pfizer, Sales Value ($m), 2009 140

Table 3: Key Pipeline Drugs Of Pfizer, 2009 141

Table 4: Top Selling Drugs of JNJ, Sales Value ($m), 2009 143

Table 5: Key Pipeline Drugs of Johnson and Johnson, 2009 144

Table 6: Top Selling Drugs of Roche, Sales Value ($m), 2009 146

Table 7: Key Pipeline Drugs of Roche, 2009 147

Table 8: Top Selling Drugs of GSK, Sales Value ($m), 2009 148

Table 9: Key Pipeline Drugs of GSK, 2009 150

Table 10: Top Selling Drugs of Novartis, Sales Value ($m), 2009 151

Table 11: Key Pipeline Drugs Of Novartis, 2009 152

Table 12: Top Selling Drugs of Sanofi-Aventis, Sales Value ($m), 2009 153

Table 13: Key Pipeline drugs of Sanofi-Aventis, 2009 155

Table 14: Top Selling Drugs of AstraZeneca, Sales Value ($m), 2009 156

Table 15: Key Pipeline Drugs of AstraZeneca, 2009 158

Table 16: Top Selling Drugs of Merck ,Sales Value ($m), 2009 160

Table 17: Key Pipeline Drugs of Merck, 2009 161

Table 18: Top Selling Drugs of Bayer HealthCare, Sales Value ($m), 2009 162

Table 19: Key Pipeline Drugs of Bayer, 2009 163

Table 20: BLAs Approved by FDA in 2009 164

Table 21: NME Approved by FDA in 2009 165

Table 22: Key Warning Letters by FDA to Pharmaceutical Companies, 2009 168

Table 23: Key Drug Approvals by EMA in 2009 169

Table 24: Key NDA and Drug Approvals by MHLW, Japan, 2009 1711.2

List of Figures

Figure 1: Global Pharmaceutical Market, Market Share of Top Manufacturers(%), 2009 13

Figure 2: Global Pharmaceutical Industry, Market Share by Therapeutic Area, Global, Sales Value(%), 2009 14

Figure 3: Cardiovascular Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 17

Figure 4: Cardiovascular Therapeutics ,Global, Market Share by Indication(%), 2009 and 2016 18

Figure 5: Cardiovascular Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 18

Figure 6: Cardiovascular Therapeutics Market, Global, M&A Deals by Geography, 2009 -2010 21

Figure 7: Cardiovascular Therapeutics Market, Global, M&A Deals by Value ($), 2009-2010 22

Figure 8: Respiratory Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 23

Figure 9: Respiratory Therapeutics ,Global, Market Share by Indication(%), 2009 and 2016 24

Figure 10: Respiratory Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 24

Figure 11: Respiratory Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 26

Figure 12: Respiratory Therapeutics Market, Global, M&A Deals by Value($), 2009-2010 26

Figure 13: Musculoskeletal Disorder Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 28

Figure 14: Musculoskeletal Therapeutics , Market Share by Indication, Global, 2009 and 2016 29

Figure 15: Musculoskeletal Disorder Therapeutics Market, Global, Drivers and Restraints, 2009-2010 29

Figure 16: Musculoskeletal Therapeutics Market, Global, M&A Deals by Geography (2009-2010) 31

Figure 17: Musculoskeletal Therapeutics Market, Global, M&A Deals by Value ($), 2009-2010 32

Figure 18: Oncology Therapeutics Market, Global, Market Share of Top Manufacturers(%), 2009 33

Figure 19: Global Oncology Market, Global, Market Share by Indication (%), 2009 and 2016 33

Figure 20: Oncology Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 34

Figure 21: Oncology Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 36

Figure 22: Oncology Therapeutics Market, Global, M&A Deals by Value ($), 2009-2010 37

Figure 23: CNS Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 38

Figure 24: CNS Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 39

Figure 25: CNS Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 40

Figure 26: CNS Therapeutics Market, Global, M&A Deals by Geography, 2009-2010 42

Figure 27: CNS Therapeutics Market, Global, M&A Deals by Value ($), 2009 43

Figure 28: Autoimmune Disease Therapeutics Market, Global, Market Share of Top Manufacturers(%), 2009-2010 44

Figure 29: Autoimmune Disorders Market, Global, Sales by Indication (%), 2009 and 2016 45

Figure 30: Autoimmune Disease Therapeutics Market, Global, Market Drivers and Restraints, 2009 45

Figure 31: Autoimmune Disease Therapeutics Market, Global ,M&A Deals by Geography, 2009 47

Figure 32: Autoimmune Disease Therapeutics Market, Global ,M&A Deals by Value($), 2009 48

Figure 33: Gastrointestinal Therapeutics Market, Market Share of Top Manufacturers (%), 2009 49

Figure 34: Gastrointestinal Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 49

Figure 35: Gastrointestinal Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 50

Figure 36: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Geography, 2009 52

Figure 37: Gastrointestinal Disorder Therapeutics Market, Global, M&A Deals by Value ($), 2009 52

Figure 38: Dermatology Therapeutics Market, Global, Market Share of Top Manufacturers, 2009 53

Figure 39: Dermatology Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 54

Figure 40: Dermatology Therapeutics Market, Global, Market Drivers and Restraints, 2009-2010 55

Figure 41: Dermatology Therapeutics Market , Global, M&A Deals by Geography, 2009-2010 56

Figure 42: Dermatology Therapeutics Market , Global, M&A Deals by Value ($), 2009 57

Figure 43: Ophthalmology Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 58

Figure 44: Ophthalmology Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 59

Figure 45: Global Ophthalmology Therapeutics Market, Drivers and Restraints, 2009 60

Figure 46: Ophthalmology Therapeutics Market, Global, M&A deals by Geography ($), 2009 61

Figure 47: Ophthalmology Therapeutics Market, Global, M&A deals by Value ($), 2009 62

Figure 48: Men's Health Market, Global, Market Share of Top Manufacturers(%), 2009 63

Figure 49: Men's Health Market, Global, Sales by Indication (%), 2009 and 2016 63

Figure 50: Men's Health Market, Global, Market Drivers and Restraints, 2009-2010 64

Figure 51: Men's Health Market, Global, M&A Deals by Geography(%), 2009-2010 65

Figure 52: Men's Health Market, Global, M&A Deals by Value,($), 2009-2010 66

Figure 53: Women's Health Market, Global, Market Share of Top Manufacturers, 2009 67

Figure 54: Women's Health Market, Global, Market Share by Indication (%), 2009 and 2016 67

Figure 55: Women's Health Market, Global, Drivers and Restraints, 2009-2010 68

Figure 56: Women's Health Market, Global, M&A Deals by Geography(%), 2009-2010 69

Figure 57: Women's Health Market, Global, M&A Deals by Geography, ($), 2009-2010 70

Figure 58: Blood Disorders Market, Global, Market Share of Top Manufacturers(%), 2009 71

Figure 59: Blood Disorder Therapeutics Market, Global, Market Share by Indication (%), 2009 and 2016 71

Figure 60: Blood Disorders Market, Global, Market Drivers and Restraints, 2009-2010 72

Figure 61: Blood Disorders Market, Global, Major M&A Deals by Geography, (%), 2009-2010 74

Figure 62: Blood Disorders Market, Global, M&A Deals by Value, ($), 2009-2010 75

Figure 63: Urological Disorders Market, Global, Market Share of Top Manufacturers(%), 2009 76

Figure 64: Urological Therapeutics Market, Global, Sales by Indication (%), 2009 and 2016 77

Figure 65: Urological Disorders Market, Global, Market Drivers and Restraints, 2009-2010 78

Figure 66: Urological Disorders Market, Global, Major M&A Deals by Geography, 2009-2010 80

Figure 67: Urological Disorders Market, Global, M&A Deals by Value($),2009-2010 81

Figure 68: M&A Deals by Therapeutic Area, Global, Market Share(%), 2009-2010 135

Figure 69: Major M&A Deals by Geography, Global, 2009-2010 136

Figure 70: Major M&A Deals by Value($), Global, 2009-2010 137

Figure 71: GBI Research Market Forecasting Methodology, 2010 176

Companies mentioned

To order this report:

Pharmaceutical Industry: Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker